NEW YORK (GenomeWeb News) – Med BioGene said after the close of the market on Thursday that it had no revenues for the third quarter ended Sept. 30.

The firm had posted revenues of C$1.5 million (US$1.5 million) for the third quarter a year ago. The revenues last year were derived from licensing payments.

Med BioGene's net loss for the quarter was C$79,633, or break even on a per-share basis, compared to a profit of C$1.6 million, or C$.02 per share, a year ago, according to a document filed with Canadian regulators.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.